Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neuroendocrine Tumors × Lutetium × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Prostatic Neoplasms 5 Urogenital Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Recurrence 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1 Neoplasms by Histologic Type 1 Neoplasms 1 Metastatic Neuroendocrine Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Lymphoproliferative Disorders 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Lymphatic Diseases 1 Lung Neoplasms 1 Immunoproliferative Disorders 1 Immune System Diseases 1 Gastro-enteropancreatic neuroendocrine tumor 1 Digestive System Neoplasms 1 Carcinoma, Adenoid Cystic 1 Breast Neoplasms 1 AIDS-Related Complex 1

Interventions

lutetium Lu 177 dotatate 33 Everolimus 29 Magnetic Resonance Spectroscopy 13 lanreotide 12 gallium Ga 68 dotatate 12 Temozolomide 11 Octreotide 11 Capecitabine 11 Nivolumab 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 surufatinib 8 pembrolizumab 8 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 3-Iodobenzylguanidine 8 Sunitinib 7 Specimen Handling 7 amino-acid, glucose, and electrolyte solution 6 90Y-octreotide, DOTA-Tyr(3)- 6 pasireotide 5 Lutetium-177 5 Fluorodeoxyglucose F18 5 Carboplatin 5 Bevacizumab 5 olaparib 4 avelumab 4 Somatostatin 4 Ipilimumab 4 Injections 4 Etoposide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06878664 2025-09-02

RIALTO

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡